Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
14
09
2020
accepted:
08
04
2021
revised:
10
03
2021
medline:
23
10
2023
pubmed:
14
5
2021
entrez:
13
5
2021
Statut:
ppublish
Résumé
Dopaminergic dysregulation is one of the leading hypotheses for the pathoetiology underlying psychotic disorders such as schizophrenia. Molecular imaging studies have shown increased striatal dopamine synthesis capacity (DSC) in schizophrenia and people in the prodrome of psychosis. However, it is unclear if genetic risk for psychosis is associated with altered DSC. To investigate this, we recruited healthy controls and two antipsychotic naive groups of individuals with copy number variants, one with a genetic deletion at chromosome 22q11.2, and the other with a duplication at the same locus, who are at increased and decreased risk for psychosis, respectively. Fifty-nine individuals (21 with 22q11.2 deletion, 12 with the reciprocal duplication and 26 healthy controls) received clinical measures and [18F]-DOPA PET imaging to index striatal Ki
Identifiants
pubmed: 33981004
doi: 10.1038/s41380-021-01108-y
pii: 10.1038/s41380-021-01108-y
pmc: PMC10575769
mid: EMS121959
doi:
Substances chimiques
Dopamine
VTD58H1Z2X
fluorodopa F 18
2C598205QX
Dihydroxyphenylalanine
63-84-3
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1995-2006Subventions
Organisme : NIMH NIH HHS
ID : U01 MH101722
Pays : United States
Organisme : Medical Research Council
ID : MC_U120097115
Pays : United Kingdom
Organisme : NIMH NIH HHS
ID : U01 MH101724
Pays : United States
Organisme : Medical Research Council
ID : MR/N022572/1
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
Psychopharmacology (Berl). 1987;91(4):415-33
pubmed: 2884687
Brain. 2017 May 1;140(5):1371-1383
pubmed: 28369257
Neuropsychopharmacology. 2008 May;33(6):1252-8
pubmed: 17653112
Transl Psychiatry. 2017 May 30;7(5):e1141
pubmed: 28556830
Schizophr Bull. 2017 Sep 1;43(5):1079-1089
pubmed: 28204757
Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7612-6
pubmed: 7644464
Mol Psychiatry. 2011 Sep;16(9):885-6
pubmed: 21358709
Mol Psychiatry. 2014 Jan;19(1):37-40
pubmed: 24217254
Neuropsychopharmacology. 2003 Apr;28(4):787-94
pubmed: 12655326
Psychiatry Res. 2016 Feb 28;236:206-207
pubmed: 26763109
Nat Genet. 2017 Jan;49(1):27-35
pubmed: 27869829
Neuroscientist. 2009 Dec;15(6):635-50
pubmed: 19793723
Brain. 2014 Feb;137(Pt 2):565-75
pubmed: 24334314
Biol Psychiatry. 2016 Aug 15;80(4):331-337
pubmed: 26795442
Arch Gen Psychiatry. 1999 Oct;56(10):940-5
pubmed: 10530637
Neuroimage. 2010 Apr 1;50(2):524-531
pubmed: 20034580
Schizophr Res. 2008 Dec;106(2-3):148-55
pubmed: 18849151
Biol Psychiatry. 2019 Jan 1;85(1):79-87
pubmed: 30122287
Arch Gen Psychiatry. 2009 Jan;66(1):13-20
pubmed: 19124684
Neuropsychopharmacology. 2014 Sep;39(10):2397-404
pubmed: 24718373
Biol Psychiatry. 2012 Mar 15;71(6):561-7
pubmed: 22133268
J Consult Clin Psychol. 1988 Dec;56(6):893-7
pubmed: 3204199
J Cereb Blood Flow Metab. 2003 Mar;23(3):285-300
pubmed: 12621304
JAMA Psychiatry. 2015 Apr;72(4):334-41
pubmed: 25671328
Neuroscience. 1995 Oct;68(3):955-62
pubmed: 8577387
JAMA Psychiatry. 2017 Mar 1;74(3):282-290
pubmed: 28114601
Schizophr Bull. 1990;16(1):97-110
pubmed: 2185538
Arch Gen Psychiatry. 2003 Dec;60(12):1187-92
pubmed: 14662550
Lancet. 2009 Jan 17;373(9659):234-9
pubmed: 19150704
Biol Psychiatry. 1999 Jul 1;46(1):56-72
pubmed: 10394474
J Cereb Blood Flow Metab. 1993 Jan;13(1):57-69
pubmed: 8417011
Biol Psychiatry. 2017 Jan 1;81(1):9-20
pubmed: 27720198
Transl Psychiatry. 2017 Jul 25;7(7):e1180
pubmed: 28742080
Psychol Med. 2011 Nov;41(11):2331-8
pubmed: 21426628
Am J Psychiatry. 2017 Mar 1;174(3):216-229
pubmed: 27919182
Lancet. 2014 May 10;383(9929):1677-1687
pubmed: 24315522
Am J Psychiatry. 2014 Jun;171(6):627-39
pubmed: 24577245
Aust N Z J Psychiatry. 2005 Nov-Dec;39(11-12):964-71
pubmed: 16343296
J Cereb Blood Flow Metab. 1999 Nov;19(11):1189-208
pubmed: 10566965
World Psychiatry. 2020 Feb;19(1):15-33
pubmed: 31922684
Eur J Neurol. 2012 Jan;19(1):155-62
pubmed: 22175760
Biol Psychiatry. 2008 Jan 1;63(1):114-7
pubmed: 17655830
J Psychopharmacol. 2010 Oct;24(10):1525-31
pubmed: 19406852
Transl Psychiatry. 2017 Feb 7;7(2):e1027
pubmed: 28170002
JAMA Psychiatry. 2017 Dec 1;74(12):1206-1213
pubmed: 29049482
J Cereb Blood Flow Metab. 1983 Mar;3(1):1-7
pubmed: 6822610
Acta Radiol Suppl. 1991;376:149-50
pubmed: 1666757
Neurosci Biobehav Rev. 2018 Feb;85:146-159
pubmed: 28970021
Neuropsychopharmacology. 2013 Feb;38(3):485-91
pubmed: 23093224
JAMA Psychiatry. 2016 Sep 1;73(9):963-969
pubmed: 27602560
Schizophr Bull. 2018 Oct 17;44(6):1301-1311
pubmed: 29301039
Arch Gen Psychiatry. 2012 Mar;69(3):220-9
pubmed: 22393215
Nat Commun. 2018 Jun 11;9(1):2265
pubmed: 29891954
Schizophr Bull. 1987;13(1):23-47
pubmed: 3474774
Schizophr Res. 2000 Dec 15;46(2-3):209-15
pubmed: 11120433
Mol Psychiatry. 2000 Jan;5(1):22-31
pubmed: 10673765
Med Image Anal. 1996 Jun;1(2):163-75
pubmed: 9873927
J Psychopharmacol. 2015 Feb;29(2):97-115
pubmed: 25586400
Neuropharmacology. 2020 Aug 1;172:107704
pubmed: 31299229
Am J Psychiatry. 2011 Dec;168(12):1311-7
pubmed: 21768612
Biol Psychiatry. 2013 Jul 15;74(2):106-12
pubmed: 23312565
Biol Psychiatry. 2017 Jul 1;82(1):17-25
pubmed: 27832840
J Cereb Blood Flow Metab. 1993 Jul;13(4):668-75
pubmed: 8314919
Lancet Psychiatry. 2018 Jul;5(7):573-580
pubmed: 29886042
Mol Psychiatry. 2019 Oct;24(10):1502-1512
pubmed: 29679071